Lupus & antiphospholipid syndrome
Incidence of and risk factors for myelodysplastic syndrome in patients with rheumatologic diseases
Main finding · Incidence of MDSResult — go to the resultAdjusted hazard ratio 2.61 CI 1.19–36.06Authors' conclusion
SLE is a significant risk factor for MDS among patients with rheumatologic diseases. A lower haemoglobin level at the time of diagnosis of rheumatologic disease was associated with the future development of MDS.
Study context
- Population
- Patients diagnosed with rheumatologic diseases at a tertiary care hospital, May 2009–July 202255,841 person-years of follow-up
- Exposure
- Patients with rheumatologic disease who developed myelodysplastic syndrome (MDS) vs age- and sex-matched controls with the same rheumatologic disease
- MDSn = 64
- Outcome
- Incidence of and risk factors for MDS
Methodological detailssingle tertiary care hospital, 5 age- and sex-matched controls per MDS case
- Single tertiary care hospital
- 5 age- and sex-matched controls per MDS case
Main finding
Incidence of MDS
Adjusted hazard ratio
2.61
CI 1.19–36.06
P = 0.01
Events by group
MDS
1.15/1000 PY
64 of 64
Patients with rheumatologic disease who developed MDSvs age- and sex-matched controls with the same rheumatologic disease
adjusted hazard ratio 2.61 (CI 1.19–36.06); P = 0.01
As reported in the abstract
Observational data: associations, not effects.
Further findings
- Characteristics of MDS patients
- 57.0 · median · IQR 41.0–69.0 · years
Haemoglobin at diagnosis of rheumatologic disease
- RA, SLE and AS patients with MDS had lower haemoglobin than matched controls
GC use
- MDS patients with SLE and BD had higher GC use (frequency and mean dose) than controls
Original publication
Incidence of and risk factors for myelodysplastic syndrome in patients with rheumatologic diseases. Rheumatology (Oxford). Published 27 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →